Switzerland· 67238001
Quofenix 450 mg, Tabletten
A delafloxacin product containing delafloxacinum, registered in Switzerland by A. Menarini GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Delafloxacin is registered in 10 of 19 countries.
Countries holding a registration under ATC J01MA23 (delafloxacin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 6 of them publish a price we can compare per daily dose
Delafloxacin · ATC J01MA23
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of delafloxacin costs, country by country.
Normalised to the WHO defined daily dose (0.9 g), so markets compare like for like.
- Switzerland: $210.37 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Delafloxacin · price per daily dose (0.9 g)
USD · FX 28 Sept 2026
- CH Switzerland$210.37
The record
At a glance
Swissmedic (Switzerland)- Active substance
- delafloxacinum
- Manufacturer
- A. Menarini GmbH
- Country
- Switzerland (CH)
- ATC code
- J01MA23
- ATC class
- Delafloxacin
- Defined daily dose
- 0.9 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680672380018Blist 10 StkCHF 697.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
222 interactions on record for delafloxacin.
Graded by severity as the source publishes them — 44 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Delafloxacin · interactions on record
222 records
- 44 severe
- 125 moderate
- 53 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Delafloxacin in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainQUOFENIX 450 mg COMPRIMIDOSA. Menarini Industrie Farmaceutiche Riunite S.R.L.
- FranceQUOFENIX 450 mg, compriméMENARINI ITALIE
- United KingdomQuofenix 450mg tabletsA. Menarini Farmaceutica Internazionale SRL
- IcelandQuofenixA. Menarini Industrie Farmaceutiche Riunite Srl
- NetherlandsQuofenix 450 mg, tablettenA. Menarini Industrie Farmaceutiche Riunite S.r.l.
- SwedenQuofenix 450 mg TablettA Menarini Manufacturing Logistics and Services s.r.l.
- ItalyQUOFENIX*10 cpr 450 mgA.MENARINI IND.FARM.RIUN.Srl
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Quofenix
- Liechtenstein · Quofenix
- Norway · Quofenix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/89121f7b-51af-4a52-85cc-1e48497aabd4 GET /v1/drugs/89121f7b-51af-4a52-85cc-1e48497aabd4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "delafloxacinum 450 mg",
"valid_from": "2021-12-01",
"limitations": "[{\"description\":\"Zur Behandlung akuter bakterieller Haut- und Hautstrukturinfektionen (ABSSSI) bei Erwachsenen. Dies schliesst folgende Infektionsarten ein: Cellulitis/Erysipel, Wundinfektion, grösserer kutaner Abszess oder Verbrennungswunden, deren Erythem ≥ 75cm2 beträgt und ≥ 2 Zeichen einer systemischen\\nInfektion vorliegen.<br>\\nDie QUOFENIX Tabletten dürfen erst nach 6 Dosen QUOFENIX i.v. eingesetzt werden. Die Gesamtdauer der Behandlung beträgt 5 bis maximal 14 Tage nach Ermessen des Arztes. Die Behandlung mit QUOFENIX ist nur dann angezeigt, wenn die für die Initialbehandlung dieser Infektionen empfohlenen Antibiotika als nicht geeignet erachtet werden. Die allgemein anerkannten Richtlinien für den angemessenen Gebrauch von antimikrobiellen Wirkstoffen sind zu berücksichtigen, insbesondere Anwendungsempfehlungen zur Verhinderung der Zunahme von Antibiotikaresistenz. Daher soll die Indikationsstellung und die Therapie mit QUOFENIX nur unter Anleitung eines Infektiologen erfolgen. QUOFENIX darf nur bei schwerwiegenden Infektionen und wenn keine andere geeignete Therapieoption in Frage kommt, eingesetzt werden.<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2021-12-01\"}]",
"galenic_form": "Tabl 450 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2021-12-01",
"self_retention_pct": 10
}See everything about delafloxacin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.